Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crescent BiopharmaCBIO -8.62%12 Cyclically Adjusted PB Ratio is 0.07 as of Sep. 16, 2026. GuruFocus rates CBIO with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 680 Biotechnology companies, Crescent Biopharma ranks worse than 147058.68% on this metric.
Crescent Biopharma (NAS:CBIO) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Crescent Biopharma Cyclically Adjusted PB Ratio Related Terms
Crescent Biopharma Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Crescent Biopharma's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crescent Biopharma Cyclically Adjusted PB Ratio Chart
CBIO vs SGMT, MDXG, PRME: Cyclically Adjusted PB Ratio Comparison
For the Biotechnology subindustry, Crescent Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crescent Biopharma Cyclically Adjusted PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crescent Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Crescent Biopharma's Cyclically Adjusted PB Ratio falls into.
Crescent Biopharma Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Crescent Biopharma does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.
What does a Cyclically Adjusted PB Ratio of 0.07 mean?
Crescent Biopharma (CBIO) has a Cyclically Adjusted PB Ratio of 0.07 as of Sep. 16, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Crescent Biopharma and its competitors. According to the industry distribution chart, Crescent Biopharma ranks #999999 out of 680 companies in the Biotechnology industry.
Is Crescent Biopharma's Cyclically Adjusted PB Ratio too high?
Crescent Biopharma's current Cyclically Adjusted PB Ratio is 0.07. The Biotechnology industry median Cyclically Adjusted PB Ratio is 1.58. Crescent Biopharma's value of 0.07 is 95.6% below this industry median. Based on the distribution chart, Crescent Biopharma ranks #999999 out of 680 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Crescent Biopharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's Cyclically Adjusted PB Ratio compare to SGMT and MDXG?
According to the Biotechnology industry distribution chart, Crescent Biopharma ranks #999999 out of 680 companies for Cyclically Adjusted PB Ratio. This places Crescent Biopharma in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.58. Crescent Biopharma's value of 0.07 is 95.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Biotechnology company?
The median Cyclically Adjusted PB Ratio among Biotechnology companies is 1.58, based on 680 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crescent Biopharma's current Cyclically Adjusted PB Ratio of 0.07 is 95.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Crescent Biopharma and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PB Ratio is 1.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crescent Biopharma's current Cyclically Adjusted PB Ratio is 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (CBIO) has a current Cyclically Adjusted PB Ratio of 0.07. The current Cyclically Adjusted PB Ratio is 0.07 and 95.6% below the Biotechnology industry median of 1.58. Crescent Biopharma's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Crescent Biopharma (CBIO), the current Cyclically Adjusted PB Ratio is 0.07 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
12GF Score
Get the complete analysis for CBIO
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBIO has been successfully added to your 
